Medical University of Gdansk   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Gdansk Poland (1945)

Organization Overview

First Clinical Trial
2004
NCT00211952
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Deaprtment of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk | Department of Cardiac Anaesthesiolgy UCC of Gdansk | Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk | Department of Hypertension and Diabetology - Medical Academy - Gdansk (Poland) | Department of Nephrology Transplantology and Internal Medicine. Medical University of Gdansk | Department of Nephrology Transplantology and Internal Medicine. Medical University of Gdansk. | Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk - Poland | Department of Non-Commercial Clinical Research, Medical University of Gdansk | Mecical University of Gdansk | Mecical University of Gdansk, Poland | Medical Academy, Gdansk | Medical University Gdansk | Medical University of Gdansk | Medical University of Gdańsk | Medical University of Gdansk, Department Paediatric & Adolescent Nephrology & Hypertension - Gdansk - Poland | Medical University of Gdansk, Gdansk, Poland | Medical University of Gdańsk, Gdańsk, Poland | Medical University of Gdańsk, Poland | University Clinical Centre, Gdansk | University of Gdansk

Active Ingredients

Drugs in Phase 4 Trials (18)

acetylsalicylic acid (aspirin) (1 trial)

aliskiren (tekturna) (3 trials)

clopidogrel (plavix) (1 trial)

dabigatran (pradaxa) (1 trial)

desflurane (suprane) (1 trial)

dexmedetomidine (precedex) (1 trial)

droperidol (innovar) (2 trials)

eplerenone (inspra) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

norgestimate (1 trial)

ondansetron (zofran) (1 trial)

perindopril (aceon) (1 trial)

propofol (diprivan) (2 trials)

remifentanil (ultiva) (1 trial)

sevoflurane (ultane) (1 trial)

sitagliptin (januvia) (1 trial)

telmisartan (micardis) (1 trial)

ticagrelor (brilinta) (1 trial)

Drugs in Phase 3 Trials (21)

carboplatin (paraplatin) (2 trials)

cefixime (suprax) (1 trial)

celecoxib (celebrex) (1 trial)

cisplatin (platinol) (1 trial)

clavulanate (Augmentin) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (1 trial)

fenoldopam (corlopam) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (1 trial)

ketanserin (1 trial)

metoprolol (lopressor) (1 trial)

morphine (2 trials)

nitrofurantoin (furadantin) (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

oxaliplatin (eloxatin) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

sorafenib (nexavar) (1 trial)

trimethoprim (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (7)

afatinib (gilotrif) (1 trial)

gefitinib (iressa) (1 trial)

nivolumab (opdivo) (1 trial)

osimertinib (tagrisso) (1 trial)

paclitaxel (taxol) (1 trial)

palbociclib (ibrance) (1 trial)

rostafuroxin (1 trial)

Drugs in Other Trials (18)

acetylcysteine (mucomyst) (1 trial)

albuterol (proventil) (1 trial)

amino acids (Freamine) (1 trial)

atorvastatin (lipitor) (1 trial)

cholera vaccine (Vaxchora) (1 trial)

ferric saccharose (1 trial)

fructose (1 trial)

glucose (1 trial)

ipratropium (atrovent) (1 trial)

lactobacillus plantarum (1 trial)

leucine (3 trials)

levocarnitine (carnitor) (4 trials)

losartan (cozaar) (1 trial)

midazolam (versed) (1 trial)

spironolactone (aldactone) (1 trial)

ubiquinone (1 trial)

vitamin d3 (3 trials)

xylitol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Acute Kidney Injury (Phase 3)

Atrial Fibrillation (Phase 4)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Congenital Abnormalities (Phase 3)

Coronary Artery Disease (Phase 4)

Dyspnea (Phase 3)

Essential Hypertension (Phase 2)

Fibrosis (Phase 3)

Hepatoblastoma (Phase 3)

Hypertension (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 3)

Kidney Diseases (Phase 4)

Lung Neoplasms (Phase 3)

Memory Disorders (Phase 4)

Proteinuria (Phase 4)

Pulmonary Fibrosis (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Syndrome (Phase 4)

Vesico-Ureteral Reflux (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 64